T.J.Maxx parent tops expectations as bargain goods still sell
Customers have grown more worried about tariff-related price hikes and inflation. The Framingham, Massachusetts-based retailer's model offers lower-priced items from popular brands, and has the ability to swap its inventory based on availability.
TJX is thriving while other retailers struggle to cope with shifting tariff policies from the Trump administration and economic uncertainty keeping shoppers' wallets tight.
Advertisement
'While its closest peer set, department stores, continues to face margin pressure and store closures, TJX delivered margin improvement and continued to grow its footprint, cementing its healthy position in a mixed economic climate,' said Suzy Davidkhanian, an analyst at Emarketer.
TJX has been aggressively snapping up excess merchandise from brands looking to clear out piles of unsold goods. Management said there were 'excellent buying opportunities' in the market and pounced on those deals. Total inventories rose nearly 14 percent to $7.4 billion for the quarter.
Advertisement
As retailers report earnings, investors and analysts are looking for clues about price changes and shopping behaviors. Among their main questions are how much of the added costs retailers are absorbing.
Walmart Inc. is expected to report later this week.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Sony is increasing the price of the PlayStation 5 as new tariffs take hold
Sony will raise the price of PlayStation 5 consoles, the company announced on Wednesday. These changes will be effective as of Thursday, August 21. Citing 'a challenging economic environment' — which appears to reference President Trump's tariffs on imported products — Sony is increasing console prices by about $50. In the U.S., the prices will increase to $549.99 for the PlayStation 5, $499.99 for the PlayStation 5 Digital Edition, and $749.99 for the PlayStation 5 Pro. On July 31, the White House announced a 15% tariff on Japan. The company said that it does not have plans to change prices in other countries, nor does it intend to hike the cost of accessories. However, Sony already raised prices for PlayStation consoles sold in Europe, Australia, and New Zealand in April, citing the same challenging environment. In some regions, Sony previously increased console prices in 2022 due to inflation, but U.S. markets were not impacted at the time. Some of Sony's peers have also announced pricing changes to gaming products amid the news of Trump's tariffs. Microsoft indicated in May that it would increase console prices by $80 to $100, while also increasing the prices of some games, controllers, and accessories. Nintendo chose to raise the prices of some accessories for the new Nintendo Switch 2 console, but not the console itself. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
30 minutes ago
Starbucks Pumpkin Spice Latte returns soon, when to get your PSL fix
Starbucks has announced the highly anticipated return date of the fall fan-favorite Pumpkin Spice Latte. When does Starbucks' Pumpkin Spice Latte come out? Although the fall equinox isn't until Sept. 22, the cultural phenomenon and seasonal sensation drink that first hit the Seattle-based coffee chain's menus more than 20 years ago will officially be back at Starbucks before then, on Aug. 26. Consumer interest in the seasonal spice-laden lattes has spiked earlier than ever, according to Google Trends, which showed an uptick in searches starting in mid-June vs. mid-July in 2024. New fall menu items coming to Starbucks this PSL season With the unofficial start of fall at Starbucks coffeehouses come more returning favorites and a new selection of drinks and bites. First up is a new Pecan Oatmilk Cortado, a coffee drink with a 1:1 ratio of espresso to steamed milk, amplifying another nutty fall flavor. In keeping with the high-protein food trends, Starbucks has added another option to its already popular egg bites with a new Italian sausage version. Returning alongside the PSL is the fan-favorite Pumpkin Cream Cold Brew, Iced Pumpkin Cream Chai and Pecan Crunch Oatmilk Latte. Starbucks fall flavors hit grocery stores this summer With more people tapping into the trend of Summerween, Starbucks announced its at-home line of fall products early, with K-Cup pods and Nespresso capsules already available in grocery stores. Joining the lineup this year is a new Starbucks Maple Pecan Latte-inspired nondairy creamer. The Starbucks Pumpkin Spice Latte-inspired creamer is also back in both dairy and non-dairy options. At-home coffee fans can also snag Starbucks' Fall Blend or Smoked Butterscotch Flavored Coffee, available in K-Cup Pods and roast and ground varieties, and Starbucks Pumpkin Spice Flavored Coffee, which is also available as Nespresso for Vertuo capsules. Starbucks' ready-to-drink beverages -- including the Pumpkin Spice Flavored Coffee, available in RTD Iced Espresso and RTD Frappuccino Chilled Coffee Drink -- are available as well.
Yahoo
35 minutes ago
- Yahoo
Novo Nordisk Soars After 50% Ozempic Discount, Liver Treatment Approval
Cash truly is king. On Monday, shares in Novo Nordisk jumped 4% after the drugmaker announced that US customers who pay out-of-pocket will be able to buy its blockbuster diabetes drug Ozempic for less than half the list price. In a year of struggles against copycats, an emboldened chief rival and political pressure over high prices, executives are no doubt hoping the discount will prove a crowning achievement. READ ALSO: SoftBank Acquires a 2% Stake in Embattled Intel and Brokers Chafe Under Abrupt Expansion of Steel, Aluminum Tariffs A Letter from Washington Without insurance, Ozempic can set back US customers roughly $1,350 a month, or enough to rent a one-bedroom apartment in Kansas City (where the local barbecue might have you in need of a GLP-1 prescription). That hefty price tag has led to a bipartisan pushback in Washington, including from President Donald Trump, who sent a letter to Novo last month demanding executives lower prices for their company's treatments. Trump also urged drugmakers to develop direct-to-consumer sales models for their medicines. Americans spent $98 billion out of pocket on prescriptions last year, a 25% cumulative increase over five years, according to IQVIA, while a majority worry that prescription costs are unaffordable, according to KFF polling. Meanwhile, Novo has its own incentives to lower prices. For one, customers flocked to cheaper copycat drugs that exploded in popularity during a multi-year GLP-1 shortage, one that the FDA declared over earlier this year. And the company's chief rival in the GLP-1 space, Mounjaro- and Zepbound-maker Eli Lilly, has been binge-eating market share. Last month, the pressure prompted Novo to slash its sales and profit forecasts, prompting a massive selloff on Wall Street (shares are down 37% this year). On Monday, the company signalled it will defend its turf: Novo said cash-paying Americans can now buy Ozempic for $499 per month through its official website, its patient assistance program, its newly launched direct-to-consumer online pharmacy, or through discount telehealth platform GoodRx. The move follows Novo's decision to halve the price of weight-loss treatment Wegovy in March. Its price reductions follow similar cuts from Eli Lilly, which slashed the prices of both its weight loss and obesity GLP-1 drugs in March. David Ricks, Eli Lilly's CEO, said at the time that about 10% of the 1 million people who bought Zepbound did so from the company's website. MASHing Success: Monday's news came on the heels of a Friday victory for Novo, when Wegovy received FDA approval to treat metabolic dysfunction-associated steatohepatitis (MASH), a liver condition that affects roughly 5% of US adults, potentially opening up a market of millions of new customers. It was the first GLP-1 treatment to be approved for MASH, giving Novo a leg up against its biggest competitor. Rival Lilly, meanwhile, has run trials, inked deals and even made an acquisition earlier this year with an eye to rolling out MASH treatments. This post first appeared on The Daily Upside. To receive delivering razor sharp analysis and perspective on all things finance, economics, and markets, subscribe to our free The Daily Upside newsletter.
